

**Date and Time:** 4<sup>th</sup> April 2013 10:00-16:00

**Minutes:** Confirmed

**Multiple Sclerosis GDG Meeting 6**

**Place:** Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ

**Present:** GDG

1. Paul Cooper	PC
2. Jeremy Chataway	JC
3. Peter Brex	PB
4. Wendy Hendrie	WH
5. Susan Hourihan	SH
6. Noreen Barker	NB
7. Richard Warner	RW
8. Aleks de Gromoboy	ADG
9. Ann Hodgson	AH
10. Emma Rowe	ER

NCGC Technical team

11. Norma O'Flynn	NOF
12. Sharon Swain	SS
13. Mark Perry	MP
14. Amy Kelsey	AK
15. Dave Wonderling	DW
16. Krishna Chinthapalli	KC
17. Betta Fenu (for points 5-8)	BF
18. Lina Gulhane (for point 8)	LG

NICE:

1. Clifford Middleton	CM
2. Jaimella Espley	JE

Apologies

1. David Kernick	DK
2. Pamela Bostock	PB

## Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 6. Apologies were received from David Kernick and Pamela Bostock. The Chair introduced Dave Wonderling, NCGC Head of Health Economics and Jaimella Espley, NICE Senior Medical Editor, to the GDG.

2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests

JC declared the following personal pecuniary interest: he attended the MS Debating Society as a guest of Merck Serono; he attended the AAN with travel and accommodation paid by Novartis and the following non pecuniary interest: he attended an educational day for which he received an honorarium from Novartis that will be paid into the research fund.

PB declared the following personal pecuniary interest: he attended the MS Debating Society as a guest of Merck Serono.

All other GDG members had no change in their previous declarations.

3. The Chair introduced Mark Perry, NCGC Research Fellow, who presented the clinical evidence of the pharmacological treatment of spasticity for adults with MS. The GDG discussed the evidence presented. The Chair thanked MP for his presentation.
4. The Chair introduced Dave Wonderling, NCGC Health of Health Economics, who presented the health economic evidence of the pharmacological treatment of spasticity for adults with MS. The GDG discussed the evidence presented and developed draft recommendations. The Chair thanked DW for his presentation.
5. The Chair introduced Jaimella Espley, NICE Senior Medical Editor, who gave a presentation to the GDG on the role of the editor in guideline development. The Chair thanked JE for her presentation.
6. MP then updated the GDG on additional evidence on pregnancy and vaccinations identified for the modifiable risk factors review. The group discussed the evidence and reviewed the draft recommendations. The Chair thanked MP for his presentation.
7. The Chair introduced Betta Fenu, NCGC Health Economics Lead, who presented a costs update on IV versus oral steroids to the group. The GDG reviewed and discussed the evidence presented and developed draft recommendations informed by this analysis. The Chair thanked BF for her presentation.
8. SS then led discussion with the GDG on the research protocol for 1 clinical question. The following research protocol was discussed and agreed by the group:
  - For adults with MS, what is the clinical evidence and cost effectiveness of the non-pharmacological programmes (including self-management) for: fatigue, spasticity, mobility, pain, ataxia and tremor.
9. There was no other business. The Chair closed the meeting and thanked everyone for attending.

## **Notes**

### **Date, time and venue of the next meeting**

10. 24<sup>th</sup> May 2013, 10:00-16:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ